

Summary of changes between MMGv6.0 and MMGv7.0

Drug Change(s)

- 100 New Drugs
 - 94 New FDA approved drugs included
 - 6 Existing drugs added that are newly eligible to Medicare Part D
- 10 drugs removed due to manufacturer discontinuation

Indication Addition(s)

- 1 New indication
Buprenorphine: Opioid Analgesics, Long-acting

USP Category Change(s)

- New Categories (0)
- Renamed Categories (3)

MMG v6.0	MMG v7.0 - New
Therapeutic Nutrients/ Minerals/ Electrolytes	Electrolytes/Minerals/Metals/Vitamins
Enzyme Replacement/ Modifiers	Genetic or Enzyme Disorder: Replacement, Modifiers, Treatment
Hormonal Agents, Suppressant (Parathyroid)	Drugs reclassified under Metabolic Bone Disease Agents. USP Category Hormonal Agents, Parathyroid removed.

USP Class Changes

- New Classes (3)
 1. Treatment Adjuncts (in the Antineoplastics Category)
 2. Pulmonary Fibrosis Agents
 3. Anti-hepatitis C(HCV) Agents, Direct Acting*
Anti-hepatitis C(HCV) Agents, Other*

*This class was created as a result of dividing the USP Class Anti-hepatitis C (HCV) Agents from USP MMGv6.0

- Renamed Classes (4):

MMG v6.0	MMG v7.0 - New
Monoclonal Antibodies	Monoclonal Antibody/Antibody-Drug Conjugate
Electrolyte/Mineral/Modifiers	Electrolyte/Mineral/Metal Modifiers
Angioedema (HAE) Agents	Angioedema Agents
Coagulants	Hemostasis Agents